Technical Analysis for INVA - Innoviva, Inc.

Grade Last Price % Change Price Change
grade F 11.12 -2.37% -0.27
INVA closed down 2.37 percent on Wednesday, September 18, 2019, on 84 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical INVA trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
180 Bearish Setup Bearish Swing Setup -2.37%
NR7 Range Contraction -2.37%
20 DMA Support Bullish -3.56%
Overbought Stochastic Strength -3.56%
Bearish Engulfing Bearish -2.97%
Weak + Overbought Other -2.97%
Weak, Overbought and Reversal Signs Reversal -2.97%
Overbought Stochastic Strength -2.97%
Weak + Overbought Other -4.22%

Older signals for INVA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist collaboration agreement and the strategic alliance agreement with Glaxo Group Limited (GSK). The company is also entitled to a 15% interest in future payments made by GSK relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy, as well as in combination with other therapeutically active components, such as an inhaled corticosteroid, and other product or combination of products that might be discovered and developed under its LABA collaboration agreement with GSK. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance, Inc. was founded in 1996 and is headquartered in South San Francisco, California.
Medicine Drugs Glucocorticoids Organofluorides
Is INVA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.54
52 Week Low 10.76
Average Volume 574,077
200-Day Moving Average 14.5174
50-Day Moving Average 11.8912
20-Day Moving Average 11.303
10-Day Moving Average 11.417
Average True Range 0.3365
ADX 21.74
+DI 18.3513
-DI 25.3504
Chandelier Exit (Long, 3 ATRs ) 10.7305
Chandelier Exit (Short, 3 ATRs ) 11.7695
Upper Bollinger Band 11.7881
Lower Bollinger Band 10.8179
Percent B (%b) 0.31
BandWidth 8.583562
MACD Line -0.1127
MACD Signal Line -0.1669
MACD Histogram 0.0543
Fundamentals Value
Market Cap 1.22 Billion
Num Shares 109 Million
EPS 0.80
Price-to-Earnings (P/E) Ratio 13.90
Price-to-Sales 7.61
Price-to-Book 0.00
PEG Ratio 0.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.71
Resistance 3 (R3) 11.77 11.64 11.61
Resistance 2 (R2) 11.64 11.49 11.61 11.58
Resistance 1 (R1) 11.38 11.39 11.31 11.32 11.55
Pivot Point 11.24 11.24 11.21 11.21 11.24
Support 1 (S1) 10.98 11.09 10.92 10.92 10.69
Support 2 (S2) 10.85 11.00 10.82 10.66
Support 3 (S3) 10.59 10.85 10.63
Support 4 (S4) 10.53